IP Library Granted Patent US 10,781,260
Granted Patent B2
US 10,781,260 · App. 16/323,968 · Granted Sep 22, 2020

Anti-OX40 binding proteins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,781,260
App. No.
16/323,968
Granted
Sep 22, 2020
Kind
B2
Abstract

The present disclosure provides anti-OX40 antibodies, and antigen-binding portions thereof. In certain embodiments, the antibodies or fragments thereof, are used for the treatment of cancer.

Claims (11)

1. An isolated anti-OX40 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 24; and comprises a light chain variable domain comprising the amino acid sequence SEQ ID NO: 25.

2. The anti-OX40 antibody, or antigen-binding fragment thereof, of claim 1 , wherein the antibody is a human antibody.

3. The anti-OX40 antibody of claim 1 , which is an IgG.

4. The anti-OX40 antibody of claim 1 , wherein the antibody is an IgG1, IgG2, IgG3 or an IgG4 isotype.

5. The anti-OX40 antibody, or antigen-binding fragment thereof, of claim 1 , wherein the antigen-binding fragment is a Fab fragment or an scFv.

6. A pharmaceutical composition comprising the anti-OX40 antibody, or antibody fragment of claim 1 , and a pharmaceutically acceptable carrier.

7. An isolated anti-OX40 antibody, comprising:

a heavy chain and a light chain, wherein

(i) the heavy chain comprises: a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:118, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:119, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:120; and

(ii) the light chain comprises: a light chain CDR1 having the amino acid sequence of SEQ ID NO:121, a light chain CDR2 having the amino acid sequence of SEQ ID NO:122, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:123.

8. The isolated anti-OX40 antibody of claim 7 , wherein the antibody is a human antibody.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2024
From: SORRENTO THERAPEUTICS, INC.
To: VIVASOR, INC.
Reel/Frame 067395/0311 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Sep 21, 2023
From: SCILEX HOLDING COMPANY
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 065017/0844 →
RELEASE OF SECURITY INTEREST Recorded Aug 11, 2023
From: JMB CAPITAL PARTNERS LENDING, LLC
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 064571/0848 →
SECURITY INTEREST Recorded Jul 31, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: SCILEX HOLDING COMPANY
Reel/Frame 064441/0575 →
SECURITY INTEREST Recorded Apr 6, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: JMB CAPITAL PARTNERS LENDING, LLC
Reel/Frame 063283/0063 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2020
From: BRESSON, DAMIEN
To: SORRENTO THERAPEUTICS, INC.
Reel/Frame 051992/0800 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2019
From: BRESSON, DAMIEN
To: INC., SORRENTO T, INC.
Reel/Frame 050138/0075 →